Target validation in drug discovery

著者

• Metcalf, Brian W.
• Dillon, Susan

書誌事項

Target validation in drug discovery

editors, Brian W. Metcalf and Susan Dillon

Academic Press, an imprint of Elsevier, c2007

• : [hardback]

注記

"Transferred to digital printing 2010"--T.p. verso

Includes bibliographical references and index

内容説明・目次

内容説明

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

目次

I: Pharmaceutical biotechnology for target validation Chapter 1: GENERATION OF TRANSGENIC ANIMALS Chapter 2: TARGET VALIDATION IN CHEMOGENOMICS II: Target validation for biopharmaceutical drug discovery Chapter 3: CETUXIMAB (ERBITUX (R)), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER Chapter 4: MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER Chapter 5: VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASES Chapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASE Chapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION III: Validating targets of small molecule approaches Chapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB Chapter 10: PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS Chapter 11: IKK-2/NF-?B-DEPENDENT TRANSCRIPTION Chapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTS Chapter 13: THE DISCOVERY OF ELTROMBOPAG, AN ORALLY BIOAVAILABLE TpoR AGONIST Chapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDY INDEX

「Nielsen BookData」 より

詳細情報

• NII書誌ID(NCID): BB17403512
• ISBN:
  • 9780123693938
• LCCN: 2006049868
• 出版国コード: ne
• タイトル言語コード: eng
• 本文言語コード: eng
• 出版地: Amsterdam ; Tokyo
• ページ数/冊数: xii, 279 p.
• 大きさ: 27 cm
• 分類:
  • LCC : RM301.63
  • DC22 : 615/.19
• 件名:
  • LCSH : Drug development
  • LCSH : Drugs -- Testing
  • LCSH : High throughput screening (Drug development)
  • MESH : Drug Design
  • MESH : Drug Delivery Systems
  • MESH : Technology, Pharmaceutical
  • MESH : Biopharmaceutics